Free Trial

Biohaven (BHVN) Stock Price, News & Analysis

Biohaven logo
$46.81 +0.51 (+1.10%)
(As of 11/20/2024 ET)

About Biohaven Stock (NYSE:BHVN)

Key Stats

Today's Range
$44.95
$47.17
50-Day Range
$35.75
$53.73
52-Week Range
$26.80
$62.21
Volume
785,377 shs
Average Volume
1.13 million shs
Market Capitalization
$4.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.42
Consensus Rating
Buy

Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
78th Percentile Overall Score

BHVN MarketRank™: 

Biohaven scored higher than 78% of companies evaluated by MarketBeat, and ranked 278th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biohaven has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 13 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Biohaven has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Biohaven's stock forecast and price target.
  • Earnings Growth

    Earnings for Biohaven are expected to grow in the coming year, from ($8.87) to ($6.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biohaven is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biohaven is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biohaven has a P/B Ratio of 8.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Biohaven's valuation and earnings.
  • Percentage of Shares Shorted

    9.05% of the outstanding shares of Biohaven have been sold short.
  • Short Interest Ratio / Days to Cover

    Biohaven has a short interest ratio ("days to cover") of 9.5.
  • Change versus previous month

    Short interest in Biohaven has recently decreased by 1.93%, indicating that investor sentiment is improving.
  • Dividend Yield

    Biohaven does not currently pay a dividend.

  • Dividend Growth

    Biohaven does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.05% of the outstanding shares of Biohaven have been sold short.
  • Short Interest Ratio / Days to Cover

    Biohaven has a short interest ratio ("days to cover") of 9.5.
  • Change versus previous month

    Short interest in Biohaven has recently decreased by 1.93%, indicating that investor sentiment is improving.
  • News Sentiment

    Biohaven has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Biohaven this week, compared to 5 articles on an average week.
  • Search Interest

    Only 4 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,220,920.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biohaven's insider trading history.
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

Biohaven stock target cut by analyst on model updates
Top "Sleeping Giant" Crypto In The Market Now
Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.
Biohaven Ltd. (BHVN) Receives a Buy from Morgan Stanley
See More Headlines

BHVN Stock Analysis - Frequently Asked Questions

Biohaven's stock was trading at $42.80 at the start of the year. Since then, BHVN stock has increased by 9.4% and is now trading at $46.81.
View the best growth stocks for 2024 here
.

Biohaven Ltd. (NYSE:BHVN) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by $0.03.

Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Top institutional shareholders of Biohaven include Stifel Financial Corp (6.44%), Janus Henderson Group PLC (6.16%), State Street Corp (3.22%) and FMR LLC (1.95%). Insiders that own company stock include Vlad Coric, Gregory Bailey, Matthew Buten, John W Childs, George C Clark, Irina Antonijevic, Julia P Gregory, Elyse Stock, James Engelhart and Declan Doogan.
View institutional ownership trends
.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
11/12/2024
Today
11/20/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
239
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.42
High Stock Price Target
$76.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+35.5%
Consensus Rating
Buy
Rating Score (0-4)
3.07
Research Coverage
14 Analysts

Profitability

Net Income
$-408,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
$5.34 per share

Miscellaneous

Free Float
84,942,000
Market Cap
$4.73 billion
Optionable
Optionable
Beta
1.31
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:BHVN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners